Spero Therapeutics to Receive $25 Million Milestone Payment Following Tebipenem HBr NDA Resubmission by GSK

Spero Therapeutics, Inc. -0.82%
GlaxoSmithKline plc Sponsored ADR +1.25%

Spero Therapeutics, Inc.

SPRO

2.43

-0.82%

GlaxoSmithKline plc Sponsored ADR

GSK

56.69

+1.25%

Spero Therapeutics Inc. announced that its development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK), has filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis. The NDA resubmission triggers a $25 million milestone payment to Spero Therapeutics under its License Agreement with GSK, which is expected to be received in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-325821), on December 19, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.